Approvable Letter Issued for Incontinence Implants

Share this article:

Uroplasty, Inc., of Minnetonka, Minn., announced that it has received an approvable letter from the FDA following the agency's scientific review of the safety and efficacy of Macroplastique Implants for female stress urinary incontinence.

 

The letter determined that Uroplasty's application for the implants is approvable subject to auditing of manufacturing facilities, methods and controls, and compliance with quality standards.

 

Macroplastique is a soft-tissue, injectable bulking agent. When injected by a physician into the periurethral tissues, the added “bulk” allows the urethra to close more effectively and prevents urine leakage.

Share this article:
You must be a registered member of RUN to post a comment.

More in FDA News

FDA to Lift Restrictions on Avandia for Diabetes

FDA to Lift Restrictions on Avandia for Diabetes

Not all experts are happy with granting wider access to the troubled medication, however.

FDA Approves Enlarged Prostate Urine Flow Device

FDA Approves Enlarged Prostate Urine Flow Device

UroLift system, a permanent implant, helps relieve blocked urine flow.

FDA Announces New Interactive Patient Network

FDA Announces New Interactive Patient Network

Interactive tool designed to educate patients and advocates about processes of drug development.